A stent for treating bile duct injury and its preparation method and application
By adopting a bilayer structure bile duct scaffold, combining PEGDA and Col3MA materials, embedded mesenchymal stem cells and bFGF@LNPs, the problem of insufficient scaffold mechanics and biocompatibility in the prior art is solved, and effective repair of bile duct damage is achieved. and regeneration.
Patent Information
- Application Number
- CN202410191561.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-21
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-02-21
AI Technical Summary
In the existing bile duct injury treatment methods, it is difficult for the stent to have excellent mechanical properties, biocompatibility and long-term structural stability at the same time, resulting in poor treatment results.
Using a double-layer structure, the skeleton is formed by polyethylene glycol diacrylate (PEGDA) and methacrylic III collagen (Col3MA), embedded mesenchymal stem cells and biological active factor bFGF@LNPs, through 3D Preparation of printing technology to achieve a balance between mechanical and biological properties.
The stent has excellent mechanical properties, appropriate in vivo swelling and degradation rates, which promotes the repair and regeneration of bile duct tissue, providing a simpler therapeutic option.
Smart Images

Figure CN118059311B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical biomaterials, and in particular to a stent for treating bile duct damage, and a preparation method and application thereof. Background Art
[0002] Bile duct injury (BDI) is considered a major clinical challenge in hepatobiliary surgery due to its serious complications. According to the cause of injury, BDI can be divided into iatrogenic BDI (accounting for about 90-95%) and traumatic BDI. Hepatobiliary, pancreatic and gastrointestinal surgeries can all cause iatrogenic BDI.
[0003] The commonly used treatment method in clinical practice is cholechojejunostomy. However, sphincterotomy of Oddi can lead to complications such as reflux cholangitis, bile duct restenosis and bile duct cancer. Tissue engineering and biomaterials provide alternative methods for BDI treatment. Reconstructing a bionic structure with mechanical functions to replace the bile duct can promote the ingrowth of bile duct cells and achieve bile duct tissue regeneration.
[0004] Tubular scaffolds act as a controllable extracellular environment to guide tissue repair and regeneration. Currently, a variety of manufacturing techniques (such as electrospinning, dip coating, solution casting and 3D printing) and biomaterials (such as hyaluronic acid, gelatin and polycaprolactone) can be used to manufacture single-layer or double-layer tubular tissue engineering scaffolds. Compared with single-layer tubular scaffolds made of a single material, double-layer tubular scaffolds with different functions in each layer can simultaneously obtain the best mechanical and biological properties, thereby meeting a wider range of application needs.
[0005] Although biomaterials can significantly improve cell attachment and infiltration, in order to further improve the efficiency of the scaffold, the tubular scaffold should also be embedded with living cells. Compared with acellular scaffolds, artificial bile ducts containing cholangiocytes, cholangiocytes derived from liver stem cells, and mature cholangiocytes have improved performance in promoting bile duct reconstruction. In addition, the growth and proliferation of bile ducts are regulated by bile acids, hormones, and cytokines. In other areas of tissue engineering, such as vascular tissue and liver tissue engineering, researchers widely use factors that promote tissue regeneration directly in the material. However, there are few studies on the use of carrier materials to add bioactive factors for bile duct tissue engineering.
[0006] How to make bile duct engineering scaffolds have both excellent mechanical properties and cell compatibility so as to achieve long-term structural stability and biological stability remains a challenge. Summary of the invention
[0007] In view of the above problems, the present invention provides a stent for treating bile duct injury, a preparation method and an application thereof, wherein the stent has excellent mechanical properties, appropriate in vivo swelling rate and degradation rate, and good biocompatibility.
[0008] One aspect of the present invention provides a stent for treating bile duct injury, comprising a tubular skeleton and a shell coated on the surface of the tubular skeleton, wherein the tubular skeleton material comprises polyethylene glycol diacrylate (PEGDA), a photoinitiator and a light absorber, and the shell material comprises methacryloyl-type III collagen (Col3MA), a photoinitiator, mesenchymal stem cells and a bioactive factor bFGF@LNPs, i.e., basic fibroblast growth factor (bFGF) encapsulated in carrier liposome nanoparticles (LNPs).
[0009] The scaffold adopts a double-layer structure, and the skeleton is formed by a hydrogel with good mechanical properties and cell compatibility, which can achieve a good balance between mechanical and biological properties. At the same time, the scaffold not only encapsulates mesenchymal stem cells, but also carries bioactive factor components. The bioactive factors are basic fibroblast growth factor encapsulated in liposome nanoparticles with small particle size, high biocompatibility and safety. It can promote the differentiation of mesenchymal stem cells, effectively enhance the repair and regeneration of bile duct tissue, and provide a new and simpler treatment option for bile duct-related injuries and diseases.
[0010] Preferably, the mesenchymal stem cells are bone marrow mesenchymal stem cells (BMSCs).
[0011] Preferably, the LNPs are cationic liposomes composed of SM-102, HSPC, and CHO-HP.
[0012] Preferably, the photoinitiator is lithium phenyl-2,4,6-trimethylbenzoylphosphonate LAP or Irgacure 2959; and the light absorber is tartrazine.
[0013] Another aspect of the present invention further provides a method for preparing the above-mentioned stent for treating bile duct injury, comprising the following steps:
[0014] S1 Preparation of hydrogel precursor solution:
[0015] S11 dissolving PEGDA in an aqueous solution containing a photoinitiator and a light absorber to obtain a PEGDA hydrogel precursor solution,
[0016] S12 Col3MA and the bioactive factor bFGF@LNPs are dissolved in an aqueous solution containing a light absorber, and the mesenchymal stem cells are digested and resuspended in the aqueous solution to obtain a Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution;
[0017] S2 preparation of 3D printed double-layer scaffold:
[0018] S21 3D printing and curing of PEGDA hydrogel precursor solution to obtain PEGDA tubular scaffolds.
[0019] S22 The Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution was coated on the surface of the PEGDA tubular scaffold and photocrosslinked and cured to form a PEGDA / / Col3MA / bFGF@LNPs / mesenchymal stem cell double-layer tubular scaffold.
[0020] Preferably, the PEGDA hydrogel precursor solution includes 10-20wt% PEGDA, 0.1-0.35wt% photoinitiator, and 0.05-0.07wt% light absorber; the Col3MA hydrogel precursor solution includes 5-15wt% Col3MA and 0.05%-0.07wt% light absorber; the concentration of bFGF@LNPs is 0.1-3 mg / mL, and the concentration of mesenchymal stem cells is 1×10 6 ~1×10 7 Pieces / mL.
[0021] Preferably, the PEGDA is prepared by the following method: polyethylene glycol, anhydrous toluene and triethylamine are mixed, stirred, acryloyl chloride is added, stirred, dialyzed, and freeze-dried to obtain PEGDA; the Col3MA is prepared by the following method: type III collagen and methacrylic anhydride are mixed, stirred, dialyzed, and freeze-dried to obtain Col3MA.
[0022] Preferably, the bioactive factor bFGF-LNPs are obtained by mixing HSPC / CHO-HP alcohol solution and bFGF / cationic lipid SM102 solution.
[0023] Further preferably, the bioactive factor bFGF@LNPs is obtained by dropping a bFGF / cationic lipid SM-102 solution into a vortexed HSPC / CHO-HP alcohol solution.
[0024] Further preferably, in the HSPC / CHO-HP alcohol solution, the concentration of hydrogenated soybean lecithin (HSPC) is 7.0-8.0 mg / mL; the concentration of cholesterol (CHO-HP) is 16.0-18.0 mg / mL; in the bFGF / cationic lipid SM-102 solution, the concentration of cationic lipid SM-102 is 0.5-1.5 mg / mL; and the concentration of bFGF is 0.0005-0.0015 mg / mL.
[0025] In another aspect of the present invention, a bile duct injury repairing drug preparation is provided, comprising the stent described above, or the stent prepared by the preparation method described above.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The stent of the present invention has excellent mechanical properties, appropriate swelling rate and degradation rate in vivo, and good biocompatibility. First, the PEGDA hydrogel material used in the inner layer structure of the stent has a high water content and good elasticity, and the mechanical properties can vary over a wide range of moduli. The tubular structure constructed by 3D printing PEGDA hydrogel has a regular wall surface, which is conducive to surgical sutures and promotes bile acid flow, avoiding bile leakage or bile stasis after implantation. Adding a Col3MA outer layer structure not only helps to enhance the mechanical properties and biocompatibility of the stent, but also significantly increases the roughness of the outer surface of the stent, which is conducive to cell adhesion and growth; its mixed bioactive factor bFGF@LNPs can be slowly released to stimulate the proliferation and differentiation of mesenchymal stem cells into bile duct cells, thereby effectively promoting the repair and regeneration of bile duct tissue. The stent of the present invention can be used for repairing bile duct injuries. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 For effect verification example 1, PEG and PEGDA NMR test results;
[0029] Figure 2 For effect verification example 1, the results of Col3 and Col3MA nuclear magnetic resonance testing;
[0030] Figure 3 For effect verification example 2, infrared test results of PEG and PEGDA;
[0031] Figure 4 For effect verification example 2, the infrared test results of Col3 and Col3MA;
[0032] Figure 5 TEM image of LNP for effect verification example 3;
[0033] Figure 6 TEM image of bFGF@LNPs for effect verification example 3;
[0034] Figure 7 This is the appearance diagram of the stent prepared in Example 1;
[0035] Figure 8 The stent swelling curve for effect verification example 4;
[0036] Fig. 9 The stent degradation curve for effect verification example 5;
[0037] Fig.10 This is the result of in vitro biocompatibility test of bFGF@LNPs liposomes in effect verification example 6;
[0038] Fig.11This is a graph showing the in vitro biocompatibility test results of PEGDA / / Col3MA scaffold and PEGDA / / Col3MA / bFGF@LNPs scaffold in effect verification example 7. DETAILED DESCRIPTION
[0039] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the relevant drawings. The preferred embodiments of the present invention are given in the drawings. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0040] In the description of the present invention, unless otherwise clearly defined, terms such as heating, cleaning, weighing, freezing, etc. should be understood in a broad sense, and technicians in the relevant technical field can reasonably determine the specific meanings of the above terms in the present invention in combination with the specific content of the technical solution.
[0041] In the description of the present invention, the description with reference to the terms "some embodiments", "examples", etc. means that the specific methods and materials described in conjunction with the embodiments or examples are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific methods and materials described can be combined in any one or more embodiments or examples in a suitable manner.
[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0043] Unless otherwise specified, the reagents, materials, and equipment used in the examples of the present invention are all commercially available; the test methods, unless otherwise specified, are all conventional test methods in the art.
[0044] The present invention provides a stent for treating bile duct injury, comprising a tubular skeleton and a shell coated on the surface of the tubular skeleton, wherein the tubular skeleton material comprises polyethylene glycol diacrylate (PEGDA), a photoinitiator and a light absorber, and the shell material comprises methacrylylated type III collagen (Col3MA), a photoinitiator, mesenchymal stem cells and a bioactive factor bFGF@LNPs, i.e., basic fibroblast growth factor (bFGF) encapsulated in carrier liposome nanoparticles (LNPs).
[0045] The scaffold adopts a double-layer structure, and the skeleton is formed by a hydrogel with good mechanical properties and cell compatibility, which can achieve a good balance between mechanical and biological properties. At the same time, the scaffold not only encapsulates mesenchymal stem cells, but also carries bioactive factor components. The bioactive factors are basic fibroblast growth factor encapsulated in liposome nanoparticles with small particle size, high biocompatibility and safety. They can slowly release and stimulate the proliferation and differentiation of mesenchymal stem cells into bile duct cells, which can effectively enhance the repair and regeneration of bile duct tissue, and provide a new and simpler treatment option for bile duct-related injuries and diseases.
[0046] There is no particular limitation on the types of the photoinitiator and the light absorber, as long as they have good biocompatibility and can be cured quickly. In some embodiments, the photoinitiator may be lithium phenyl-2,4,6-trimethylbenzoylphosphonate (LAP) or Irgacure 2959; the light absorber may be tartrazine.
[0047] Mesenchymal stem cells are mainly used to accelerate the repair of injuries. They can be isolated and prepared from tissues such as bone marrow, fat, amniotic fluid, and umbilical cord blood. In some embodiments, they are bone marrow mesenchymal stem cells BMSCs.
[0048] Bioactive factors are also used to accelerate repair, and cell growth factors such as basic fibroblast growth factor are usually selected. The present invention selects basic fibroblast growth factor (bFGF) encapsulated in carrier cationic lipid nanoparticles (LNP) bFGF@LNPs, which have a small particle size and high biocompatibility and safety. In some embodiments, the cationic lipid is a cationic liposome composed of SM-102, HSPC and CHO-HP.
[0049] The present invention also provides a method for preparing the above-mentioned stent for treating bile duct injury, comprising the following steps:
[0050] S1 Preparation of hydrogel precursor solution:
[0051] S11 PEGDA is dissolved in an aqueous solution containing a photoinitiator and a light absorber to obtain a PEGDA hydrogel precursor solution.
[0052] S12 Col3MA and the bioactive factor bFGF@LNPs are dissolved in an aqueous solution containing a light absorber, and the mesenchymal stem cells are digested and resuspended in the aqueous solution to obtain a Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution;
[0053] S2 preparation of 3D printed double-layer scaffold:
[0054] S21 3D printing and curing of PEGDA hydrogel precursor solution to obtain PEGDA tubular scaffolds.
[0055] S22 The Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution was coated on the surface of the PEGDA tubular scaffold and photocrosslinked and cured to form a PEGDA / / Col3MA / bFGF@LNPs / mesenchymal stem cell double-layer tubular scaffold.
[0056] In some embodiments, the PEGDA hydrogel precursor solution includes 10-20wt% PEGDA, 0.1-0.35wt% photoinitiator, and 0.05-0.07wt% light absorber; the Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution includes 5-15wt% Col3MA and 0.05%-0.07wt% light absorber, which facilitates curing and molding, and the obtained scaffold has good mechanical strength and elasticity.
[0057] In some embodiments, the Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution has a mesenchymal stem cell concentration of 1×10 6 ~1×10 7 Pieces / mL.
[0058] In some embodiments, the concentration of bFGF@LNPs in Col3MA hydrogel is 0.1~3 mg / mL, and the repair effect is better.
[0059] In some embodiments, the bioactive factor bFGF@LNPs are obtained by dropping the bFGF / SM-102 solution into the vortexed HSPC / CHO-HP alcohol solution, which has a better dispersion effect.
[0060] In some embodiments, in the HSPC / CHO-HP alcohol solution, the concentration of hydrogenated soybean lecithin (HSPC) is 7.0~8.0 mg / mL; the concentration of cholesterol (CHO-HP) is 16.0~18.0 mg / mL; in the bFGF / cationic lipid SM102 solution, the concentration of cationic lipid SM102 is 0.5~1.5 mg / mL; and the concentration of bFGF is 0.0005~0.0015 mg / mL.
[0061] The PEGDA and Col3MA used in the embodiments of the present invention can be purchased from the market, and the preparation method is not limited. In some of the embodiments, PEGDA is prepared by the following method: polyethylene glycol, anhydrous toluene and triethylamine are mixed, stirred, acryloyl chloride is added, stirred, dialyzed, and freeze-dried to obtain PEGDA; Col3MA is prepared by the following method: type III collagen and methacrylic anhydride are mixed, stirred, dialyzed, and freeze-dried to obtain Col3MA.
[0062] Example 1
[0063] 1. Preparation of polyethylene glycol diacrylate (PEGDA)
[0064] 8 g of polyethylene glycol (PEG) was dissolved in 40 ml of anhydrous toluene at 40 ° C under nitrogen atmosphere, and 1.19 mL of triethylamine was added after cooling to room temperature. After stirring evenly, 0.81 mL of acryloyl chloride was added dropwise, and stirred at room temperature for 2 h. The resulting polymer was precipitated in n-hexane, and the precipitate was further purified by toluene and n-hexane three times. The purified PEGDA was then dissolved in deionized water and dialyzed (MW: 1000 Da) for 3 days, centrifuged at 10,000 rpm for 10 minutes to remove impurities, and the supernatant was lyophilized.
[0065] 2. Preparation of methacrylylated type III collagen (Col3MA)
[0066] Weigh 2 g of type III collagen (Col3) and dissolve it in 100 mL of deionized water, adjust the pH to 7, add 2 mL of methacrylic anhydride (MA), and react at room temperature for 24 h. The product Col3MA is dialyzed in deionized water using a 3500 Da dialysis bag, centrifuged at 10,000 rpm for 15 minutes to remove impurities, and the supernatant is freeze-dried.
[0067] 3. Preparation of bioactive factor bFGF@LNPs
[0068] (1) Weigh 7.4 mg of hydrogenated soybean lecithin (HSPC) and 16.7 mg of high-purity cholesterol (CHO-HP) and dissolve them in 1 mL of anhydrous ethanol. Ultrasonicate and dissolve to obtain a HSPC / CHO-HP mixed solution.
[0069] (2) Take 2 μl of growth factor (bFGF) solution (0.5 μg / μl) and 1 mg of SM-102 solution, add 200 μl of DEPC water, vortex to mix, incubate in the dark for 30 min, then add 800 μl of DEPC water and vortex to mix;
[0070] (3) Use a 200 μl pipette to take 100 ul of the HSPC / CHO-HP mixed solution and slowly add it dropwise to the solution in step (2) that is being stirred to obtain bFGF-loaded liposomes (bFGF@LNPs).
[0071] 4. Preparation of Scaffold
[0072] 4.1 Preparation of hydrogel precursor solution:
[0073] 4.1.1 PEGDA was dissolved in a deionized water solution containing 0.25wt% LAP and 0.06wt% tartrate to prepare a 15wt% PEGDA hydrogel precursor aqueous solution for 3D printing ink.
[0074] 4.1.2 Col3MA and the bioactive factor bFGF@LNPs were dissolved in a deionized water solution containing 0.06wt% tartrazine to obtain a 10wt% Col3MA hydrogel precursor aqueous solution, and the concentration of the bioactive factor bFGF@LNPs was 2 mg / mL;
[0075] 4.2 Preparation of scaffolds:
[0076] 4.2.1 3D printing and curing of PEGDA hydrogel precursor solution to obtain PEGDA tubular skeleton.
[0077] 4.2.2 The PEGDA skeleton with built-in sleeve was completely immersed in the Col3MA hydrogel precursor solution. After the solution was evenly distributed on the surface of the skeleton, it was taken out and cross-linked under ultraviolet light until it was completely gelled. It was dried at room temperature and the sleeve was separated to obtain the Col3MA shell.
[0078] Figure 7 This is the appearance picture of the PEGDA / / Col3MA / bFGF@LNPs stent prepared in Example 1. It can be seen from the figure that the inner wall or the outer wall of the tubular stent is relatively regular, smooth and dense, which is conducive to surgical suturing and promoting the flow of bile acid, avoiding bile leakage or bile stasis after implantation.
[0079] The scaffold in Example 1 was not added with mesenchymal stem cells, which will be further explained below in conjunction with the effect verification example.
[0080] Effect verification example
[0081] Effect verification example 1, nuclear magnetic resonance hydrogen spectrum (1H NMR)
[0082] (1) Samples: PEG, PEGDA, Col3, Col3MA
[0083] (2) Test method: Weigh 3-5 mg of sample and dissolve it in an appropriate amount of deuterated reagent (heavy water D2O), then put it into a clean NMR tube, perform NMR structure determination at room temperature using an NMR spectrometer, and use MestReNova software for spectral analysis.
[0084] like Figure 1 , Figure 2 These are the NMR test results of PEG, PEGDA, Col3, and Col3MA. As can be seen from the figure, they all have relevant characteristic peaks, indicating that the PEGDA and Col3MA in step 1 and step 2 in Example 1 are successfully modified.
[0085] Effect verification example 2: Fourier transform infrared spectroscopy (FT-IR)
[0086] (1) Samples: PEG, PEGDA, Col3, Col3MA
[0087] (2) Test method: First, take 3-5 mg of sample and an appropriate amount of dry potassium bromide powder (mass ratio is about 5%) in an agate mortar and grind them thoroughly to make them evenly mixed. Then, take an appropriate amount of the ground sample powder and press it into a tablet (vacuum pressure 20 mmHg, pressing for 5 min) to obtain a sample slice. Set the scanning range to 4000-400 cm -1 , detected by Fourier transform infrared spectrometer.
[0088] like Figure 3 , Figure 4 These are the infrared test results of PEG, PEGDA, Col3, and Col3MA. As can be seen from the figure, they all have relevant characteristic peaks, further indicating that the PEGDA and Col3MA in step 1 and step 2 in Example 1 are successfully modified.
[0089] Effect verification example 3, transmission electron microscopy (TEM)
[0090] (1) Sample: LNP, bFGF@LNPs
[0091] (2) Test method: The sample is evenly dispersed in an aqueous solution and then observed using TEM.
[0092] like Figure 5 , Figure 6 TEM images of LNP and bFGF@LNPs. From the images, we can see that blank or bFGF-loaded liposomes appear as spheres or quasi-spheres under a transmission electron microscope, with uniform size, good dispersion, and less adhesion and accumulation.
[0093] Effect verification example 4: in vitro swelling performance of stent
[0094] (1) Sample: the scaffold obtained in Example 1
[0095] (2) Test method: The initial weight of the scaffold is recorded as M0. Then the scaffold is completely immersed in PBS buffer. Take out the scaffold, wipe off the excess water with weighing paper, and record the weight after swelling at different times as M. t , the swelling ratio is calculated as follows:
[0096] Swelling ratio = M t / M0× 100%
[0097] like Figure 8 This is the swelling curve of the stent obtained in Example 1. The stent is basically swelled to saturation after 1 to 2 hours, and the swelling rate is about 60%. This low swelling rate allows the stent to stably maintain a normal tubular structure and has less negative effects such as compression on normal tissues.
[0098] Effect verification example 5: in vitro degradation performance of stent
[0099] (1) Sample: the scaffold obtained in Example 1
[0100] (2) Test method: After the scaffold is freeze-dried, it is weighed and recorded as W0. Then, the initial scaffold is immersed in a sterile PBS (pH 7.4) solution under a sterile environment and sealed with a sealing film, placed in a constant temperature box (37°C), and the PBS solution is replaced every 3 days. At the measurement time point (1 day, 3 days, 7 days, 10 days, 14 days, 21 days), the scaffold is taken out, washed with ultrapure water and freeze-dried, and the mass is accurately weighed after drying, recorded as Wt. The degradation rate of the scaffold obtained in Example 1 is calculated according to the following formula.
[0101] Degradation rate = (W0-W t ) / W0× 100%
[0102] like Fig. 9 This is the degradation curve of the stent obtained in Example 1. As the incubation time increases, the degradation rate of the bile duct stent in PBS gradually increases. After 10 days, the stent is degraded by about 40%. The stent can maintain a stable structure for a long time, which is beneficial to the repair and regeneration of bile duct tissue.
[0103] Effect verification example 6: in vitro biocompatibility of liposomes
[0104] (1) Sample: bFGF@LNPs (200, 300, 400, 600, 800, 1000 μg / mL)
[0105] (2) Methods:
[0106] After the mouse BMSCs cells were digested and resuspended, the cells were diluted and the cell suspension was added to the cell counting plate to calculate the number of cells. According to the amount of 10,000 cells / well, they were added to a 96-well plate and cultured overnight at 5% CO2 and 37°C. After 24h, the bFGF@LNPs solution was added to the 96-well plate at 100μl / well, and 6 parallel wells were made for each material. 5% CO2, 37°C culture. After 24h±2h, the cell culture plate was removed, the culture medium in the cell culture plate was aspirated, washed with PBS, and photographed. CCK8 solution diluted with the whole culture at a ratio of 1:10 was added, 100μl / well. At the same time, 100μl of the mixture was added to the cell-free well as a negative control well, with the same number as the experimental group. 5% CO2, 37°C culture for 0.5-1h. The cell culture plate was removed and the OD value was measured at a wavelength of 450nm in an ELISA reader.
[0107]
[0108] like Fig.10The results of the in vitro biocompatibility test of bFGF@LNPs liposomes are shown in Figure 2. Overall, the cytotoxicity increases with the increase of bFGF@LNPs liposome concentration, and the change trend is obvious. Among them, the cell growth state is the best at 200 μg / mL, with a survival rate of 82.92%, which is suitable for the construction of bile duct stents.
[0109] Effect verification example 7: in vitro biocompatibility of stent
[0110] (1) Samples: scaffold PEGDA / / Col3MA (prepared in the same manner as in Example 1, except that bFGF-LNPs were not added in step 4.1.2), and scaffold PEGDA / / Col3MA / bFGF@LNPs obtained in Example 1
[0111] (2) Methods: After digestion and resuspending of mouse BMSCs cells, the cells were diluted and the cell suspension was added to a cell counting plate to count the number of cells. The cell concentration was adjusted to 100,000 per milliliter and added to the bile duct sample in a 48-well plate (500 μl / well), marked as D0, 5% CO2, and cultured at 37°C. On D1, D3 or D7, the culture medium was aspirated, CCK8 working solution was added, and a negative control well was set. 5% CO2, 37°C culture for 1 hour. The cell culture plate was removed, the liquid in each well was transferred to a 96-well plate, and the OD value was measured at a wavelength of 405 nm in an ELISA reader. The data were processed according to the relevant formula.
[0112]
[0113] like Fig.11 The results of in vitro biocompatibility test of PEGDA / / Col3MA scaffold and PEGDA / / Col3MA / bFGF@LNPs scaffold are shown in Figure 1. Compared with PEGDA / / Col3MA scaffold, the survival rate of BMSCs cells co-cultured with PEGDA / / Col3MA / bFGF@LNPs scaffold is significantly higher overall, indicating that the scaffold with bFGF-LNPs component is more conducive to BMSCs cell proliferation. At the same time, it can be seen that the co-cultured cells may proliferate faster in the first three days, and the excessive cell density on the third day caused some cells to apoptosis, that is, a temporary decrease in cell survival rate. The remaining cells continued to proliferate in the next four to seven days, and the cell survival rate increased significantly. The above results fully demonstrate that PEGDA / / Col3MA scaffold, especially PEGDA / / Col3MA / bFGF@LNPs scaffold, has good biocompatibility, which is conducive to cell growth and promotes the repair and regeneration of bile duct tissue.
[0114] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0115] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A stent for treating bile duct injury, characterized in that: It comprises a tubular frame and a shell covering the surface of the tubular frame. The tubular skeleton material comprises PEGDA, a photoinitiator and a light absorber, The shell material includes methacrylylated type III collagen Col3MA, a light absorber, mesenchymal stem cells and a bioactive factor bFGF@LNPs. The bioactive factor bFGF@LNPs is obtained by mixing a HSPC / CHO-HP alcohol solution and a bFGF / cationic lipid SM102 solution; in the HSPC / CHO-HP alcohol solution, the HSPC concentration is 7.0-8.0 mg / mL; the CHO-HP concentration is 16.0-18.0 mg / mL; in the bFGF / cationic lipid SM102 solution, the cationic lipid SM102 concentration is 0.5-1.5 mg / mL; and the bFGF concentration is 0.0005-0.0015 mg / mL.
2. The bracket according to claim 1, characterized in that: The mesenchymal stem cells are bone marrow mesenchymal stem cells (BMSCs).
3. The bracket according to claim 1, characterized in that: The photoinitiator is phenyl-2,4,6-trimethylbenzoylphosphonic acid lithium LAP or photoinitiator 2959; the light absorber is lemon yellow.
4. The method for preparing the stent according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1 Preparation of hydrogel precursor solution: S11 dissolving PEGDA in an aqueous solution containing a photoinitiator and a light absorber to obtain a PEGDA hydrogel precursor solution, S12 Col3MA and the bioactive factor bFGF@LNPs are dissolved in an aqueous solution containing a light absorber, and the mesenchymal stem cells are digested and resuspended in the aqueous solution to obtain a Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution; S2 preparation of 3D printed double-layer scaffold: S21 3D printing and curing of PEGDA hydrogel precursor solution to obtain PEGDA tubular scaffolds. S22 The Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution was coated on the surface of the PEGDA tubular scaffold and photocrosslinked and cured to form a PEGDA / / Col3MA / bFGF@LNPs / mesenchymal stem cell double-layer tubular scaffold.
5. The preparation method according to claim 4, characterized in that: The PEGDA hydrogel precursor solution includes 10-20wt% PEGDA, 0.1-0.35wt% photoinitiator, and 0.05-0.07wt% light absorber; The Col3MA / bFGF@LNPs / mesenchymal stem cell hydrogel precursor solution includes Col3MA 5-15wt%, light absorber 0.05%-0.07wt%; bFGF@LNPs concentration is 0.1-3 mg / mL; mesenchymal stem cell concentration is 1×10 6 ~1×10 7 Pieces / mL.
6. The preparation method according to claim 4, characterized in that: The PEGDA is prepared by the following method: polyethylene glycol, anhydrous toluene and triethylamine are mixed, stirred, acryloyl chloride is added, stirred, dialyzed, and freeze-dried to obtain PEGDA; The Col3MA is prepared by the following method: type III collagen and methacrylic anhydride are mixed, stirred, dialyzed, and freeze-dried to obtain Col3MA.
7. A bile duct injury repair drug preparation, characterized in that: The invention comprises the stent according to any one of claims 1 to 3, or the stent prepared by the preparation method according to any one of claims 4 to 6.
